Results 111 to 120 of about 8,062 (139)

Noninvasive Quantification of [¹⁸F]SynVesT-2 PET in Healthy Human Brains Using Simplified Reference Tissue Models. [PDF]

J Nucl Med
Hernández-Martín N, Balayeva T, Naganawa M, Asch RH, Huang Y, Carson RE, Gallezot JD, Cai Z.   +7 more
europepmc   +1 more source

PET-based molecular imaging in neurodegeneration and dementia: current and emerging radiotracers. [PDF]

Radiol Adv
Gil N, Naik P, Koran ME, Silverman D, Kako B, Chen J.   +5 more
europepmc   +1 more source

Long-Term Audiogenic Kindling Induces Pronounced Downregulation of the GABAergic System in the Hippocampus of Krushinsky-Molodkina Rats. [PDF]

Eur J Neurosci
Ivlev AP, Filippova RA, Grigorieva YS, Nikitina LS, Glazova MV, Naumova AA, Chernigovskaya EV.   +6 more
europepmc   +1 more source

Investigating Sigma-1 Receptor and Synaptic Vesicle Glycoprotein 2A as Synaptic Markers in Alzheimer's Disease: Association with Amyloid-B, Tau, and Neuroinflammation

openaire   +1 more source

Autoradiographic Mapping of Synaptic Vesicle Glycoprotein 2A in Non-Human Primate and Human Brain [PDF]

Synapse, 2020
AbstractSynaptic vesicle glycoprotein 2A (SV2A) has been previously characterized as an imaging biomarker for assessment of synaptic density in positron emission tomography (PET) studies of patients with neurological conditions. To provide detailed maps of the brain localization of SV2A autoradiography studies were carried out using the SV2A ...
Katarina Varnäs, Vladimir Stepanov
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis

CNS and Neurological Disorders - Drug Targets, 2017
Dysfunction of synaptic neurotransmitter release is closely involved in the pathogenesis of various central nervous system diseases. Synaptic vesicle glycoprotein 2A (SV2A) is a membrane protein specifically expressed in synaptic vesicles and it modulates action potential-dependent neurotransmitter release in the brain.
Yukihiro Ohno
exaly   +3 more sources

A study to determine the mechanisms underlying changes in synaptic vesicle glycoprotein 2A density in Alzheimer’s disease

Alzheimer's & Dementia, 2023
AbstractBackgroundSynaptic vesicle glycoprotein 2A (SV2A) is a transmembrane synaptic vesicle protein that regulates vesicle exocytosis and neurotransmitter release. Positron emission tomography (PET) studies reveal that the levels of SV2A are decreased in the brains of patients with Alzheimer’s disease (AD) and other brain disorders.
Ya Yin Chang, Declan King, Kristjan Holt, Scott Gladstein, Wesley A. Horton, Amanda Bevis, Daniel G Smith, Henrik Zetterberg, Sjoerd J Finnema, Tara L Spires‐Jones   +9 more
openaire   +1 more source

Synaptic Vesicle Glycoprotein 2A alterations in focal epilepsy

2023
La tomographie par émission de positrons (TEP) avec [11C]UCB-J, qui cible la glycoprotéine 2A de la vésicule synaptique (SV2A), peut démontrer une perte synaptique dans l'hippocampe épileptogène des patients atteints d'épilepsie du lobe temporal mésial (ELTm) in vivo.
openaire   +1 more source